Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study
Authors' conclusion
The prevalence of sarcopenia is considerable in patients with RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) classified by 2010 ACR/EULAR criteria (mean age 60.1±12.1 years, range 21–99 years, 86.4% female); sarcopenia by Asian Working Group for Sarcopenia (AWGS) 2025 criteria
- Participants
- 978 patients
- Outcome
- Prevalence of sarcopenia (AWGS 2025 criteria)
Main finding
As reported in the abstract
Prevalence of sarcopenia
RA
18.6%
182 events
Observational data: associations, not effects.
Further findings
Factors associated with sarcopenia
| OR (95% CI) | ||
|---|---|---|
| Male gender | 9.140 (5.211–16.029) | |
| BMI | 0.586 (0.534–0.643) | |
| Disease duration | 1.046 (1.025–1.069) | |
| RF-IgM level | 1.002 (1.000–1.003) | |
| Prednisone dosage | 1.094 (1.033–1.159) | |
| TNFi use | 0.502 (0.312–0.808) | |
| Tocilizumab use | 0.493 (0.304–0.799) | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study. RMD Open. Published 3 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →